Autopsy report · NCT03075878
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Cause of deathStaffing, sites or logistics
“Focus resources on a planned phase 2/3 study”
Life of this trial
- Registered 10 months before it started.
- Ran for about 1 year 7 months before it stopped.
- 8 participants enrolled.
- Results were posted on the registry 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- ALXN1830
- Participants
- 8
- Sites
- 10
- Countries
- Jordan, United States
Trials that died the same way
- Safety of F14 Following Total Knee Replacement
“Study superseded by alternative Phase 3 trial” - Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism
“Lack of efficacy to proceed to Phase 2” - A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
“This is phase I/II study, phase I study completed, phase II study started and enrolled 1 patient. Company strategy consideration to terminated phase 2 study finally.” - GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
“The decision not to progress the planned Phase 3 studies is a business decision based on the need to prioritise and focus resources within GSK.” - Evaluation of Biosynthetic Constructs to Replace Donor Corneas
“This study was withdrawn to be replaced with a multi-site Phase I trial.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.